Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix Cross-Vaccination in Prior Placebo Recipients
NCT02690207Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ), sponsored by GSK. Primary endpoints: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) at 30 days, Number of Subjects With Any and Related Serious Adverse Events (SAEs) at 14 months and 1 more. Started Mar 2016; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT02690207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690207.